Table 1.
Characteristics of 113 deceased MAP participants with measures of brain tocopherols and neuropathology
| Model Covariates | ||
|---|---|---|
| Age at Death (mean years, ±SD*) | 88.5 ±5.9 | |
| Females (%) | 60 | |
| Education (mean years, ±SD*) | 14.9 ±2.6 | |
| Post-mortem autopsy (mean hours, ±SD*) | 6.4 ±3.2 | |
| APOE-ε4 (% with at least one ε4 allele) | 29.5 | |
| α-tocopherol vitamin supplement dose daily intake** [n (%)] | ||
| None | 33 (31) | |
| <50 IU | 43 (41) | |
| 50–250 IU | 4 (4) | |
| 300–500 IU | 21 (20) | |
| 600+ IU | 5 (5) | |
| Pathology | ||
| Amyloid load (median area %,[ IQR*]) | 2.8 [5.5] | |
| Braak score† for neurofibrillary tangle severity (mean, ±SD*) | 3.3 ±1.3 | |
| Score Range: 0–6 | ||
| Clinical AD‡ Diagnosis | ||
| No AD Dementia [n (%)] | 75 (65) | |
| AD Dementia [n (%)] | 40 (35) | |
*
SD=Standard deviation, 407 IQR=interquartile range
**
Total dose from multi-vitamins and individual α-tocopherol supplements
†
Higher scores represent more severe neuropathology
‡
Clinical AD diagnosis based on 410 NINCDS-ADRDA criteria